UT MD Anderson and Nature to co-host conference on next-generation cancer therapeutics
Meeting Announcement
Updates every hour. Last Updated: 26-Oct-2026 00:16 ET (26-Oct-2026 04:16 GMT/UTC)
The University of Texas MD Anderson Cancer Center and Springer Nature will co-host a conference to explore the latest research on cancer therapeutics, highlighting advances in the development of next-generation treatment modalities and the technologies enabling them. “Next Generation Cancer Therapeutics” is scheduled for Oct. 6-8, 2026, on the UT MD Anderson campus.
A research paper by scientists at University of Cambridge presented an integrated bone–eye axis framework showing that lower bone mineral density is associated with higher age-related macular degeneration risk and may serve as an accessible marker of systemic aging-related retinal vulnerability.
The research paper, published on Sept 14, 2026 in the journal Cyborg and Bionic Systems.Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient’s own immune cells to eliminate the earliest cellular drivers of age-related disease. This initiative expands the company’s dual-purpose, aging-oriented discovery strategy from small molecules into RNA-encoded, in vivo cell engineering.
Published in the International Journal of Extreme Manufacturing, researchers improved the balance of strength and ductility by using laser powder bed fusion to create alternating coarse- and fine-grained regions in a zinc–copper alloy.
Study compares three deep learning approaches for finding stroke lesions on contrast-free MRI, a step toward faster, more automated screening.
When someone may be having a stroke, every minute counts, and doctors often turn first to MRI scans that do not require an injected contrast dye; these are faster to obtain and more widely available in everyday clinical settings. The catch is that these contrast-free scans, known as FLAIR sequences, can be harder for computer programs to read automatically than more detailed scans, because the damaged brain tissue often shows up faintly, in irregular shapes, and looks somewhat different from one MRI machine to the next. A new study, published ahead of print in the Journal of Intelligent Systems in Current Computer Engineering, tested three different artificial intelligence approaches to see which handles this challenge best.